BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment
Nov 22 Bristol-Myers Squibb Co :
* European Commission approves Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin
* Approval allows for expanded marketing of Opdivo in relapsed or refractory CHL in all 28 member states of EU Source text for Eikon: Further company coverage:
UPDATE 1-Arconic knowingly supplied flammable panels for use in tower -emails
LONDON, June 24 Six emails sent by and to an Arconic Inc sales manager raise questions about why the company supplied combustible cladding to a distributor for use at Grenfell Tower, despite publicly warning such panels were a fire risk for tall buildings.
RPT-Even with Whole Foods, Amazon would need many more warehouses to reshape grocery delivery
June 23 If Amazon.com Inc hopes to revolutionize grocery delivery, then its bid to buy Whole Foods Market Inc for $13.7 billion will be just the start of a long and costly process.